RefDoc
Haut

Faire une nouvelle recherche
Make a new search
Lancer la recherche


Titre du document / Document title

Phase I/II evaluation of pentostatin (2'-deoxycoformycin) in a five day schedule for the treatment of relapsed/refractory B-cell chronic lymphocytic leukaemia

Auteur(s) / Author(s)

JOHNSON S. A. (1) ; CATOVSKY D. (2) ; CHILD J. A. (3) ; NEWLAND A. C. (4) ; MILLIGAN D. W. (5) ; JANMOHAMED R. (6) ;

Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)

(1) Taunton & Somerset Hospital, Taunton, ROYAUME-UNI
(2) Royal Marsden Hospital, London, ROYAUME-UNI
(3) Leeds General Infirmary, Leeds, ROYAUME-UNI
(4) Royal London Hospital, London, ROYAUME-UNI
(5) Birmingham Heartlands Hospital, Birmingham, ROYAUME-UNI
(6) Hillingdon Hospital, Hillingdon, ROYAUME-UNI

Résumé / Abstract

The purpose of this study was to determine the efficacy and toxicity of pentostatin (2'-deoxycoformycin) administered in a five day schedule every 28 days to patients with B-cell chronic lymphocytic leukaemia (B-CLL) relapsed from or refractory to at least one line of prior chemotherapy. The initial dose level of 2 mg/m2/day was adjusted up or down by 0.5 mg/m2 in subsequent cycles on the basis of haematological and non-haematological toxicities. The five day schedule was selected because published pharmacokinetic studies had indicated that although pentostatin had an elimination half-life of approximately six hours and could inhibit plasma adenosine deaminase activity for 24 hours, recovery of enzyme activity rapidly took place and accumulation of dATP which has a toxic effect on non-replicating lymphoid cells could be increased by repeated dosing. Twenty-nine patients were entered into the study and dose-escalation was possible in nine, while dose reductions were required for five patients. Of the 24 patients evaluable for response, complete responses were achieved in two and partial responses in five for an overall response rate of 29.2%. Toxicity consisted of myelosuppression, infection, nausea and vomiting and hepatotoxicity but was experienced at acceptable levels considering the heavily pre-treated nature of the patient population. Pentostatin in this schedule has salvage activity in previously treated or resistant patients with B-CLL.

Revue / Journal Title

Investigational new drugs    ISSN  0167-6997   CODEN INNDDK 

Source / Source

1998, vol. 16, no2, pp. 155-160 (38 ref.)

Langue / Language

Anglais

Editeur / Publisher

Springer, New York, NY, ETATS-UNIS  (1983) (Revue)

Mots-clés anglais / English Keywords

Pentostatin

;

Antineoplastic agent

;

Phase I trial

;

Phase II trial

;

Chronic lymphocytic leukemia

;

Resistance

;

Relapse

;

Human

;

Chemotherapy

;

Treatment

;

Toxicity

;

Pharmacokinetics

;

Intravenous administration

;

Enzyme inhibitor

;

Adenosine deaminase

;

Chronic

;

Hydrolases

;

Enzyme

;

Malignant hemopathy

;

Lymphoproliferative syndrome

;

Mots-clés français / French Keywords

Pentostatine

;

Anticancéreux

;

Essai clinique phase I

;

Essai clinique phase II

;

Leucémie lymphoïde

;

Résistance

;

Récidive

;

Homme

;

Chimiothérapie

;

Traitement

;

Toxicité

;

Pharmacocinétique

;

Voie intraveineuse

;

Inhibiteur enzyme

;

Adenosine deaminase

;

Chronique

;

Hydrolases

;

Enzyme

;

Hémopathie maligne

;

Lymphoprolifératif syndrome

;

Mots-clés espagnols / Spanish Keywords

Pentostatina

;

Anticanceroso

;

Ensayo clínico fase I

;

Ensayo clínico fase II

;

Leucemia linfoidea

;

Resistencia

;

Recaida

;

Hombre

;

Quimioterapia

;

Tratamiento

;

Toxicidad

;

Farmacocinética

;

Vía intravenosa

;

Inhibidor enzima

;

Adenosine deaminase

;

Crónico

;

Hydrolases

;

Enzima

;

Hemopatía maligna

;

Linfoproliferativo síndrome

;

Localisation / Location

INIST-CNRS, Cote INIST : 21156, 35400007159495.0070

Nº notice refdoc (ud4) : 1627703



Faire une nouvelle recherche
Make a new search
Lancer la recherche
Bas